Janus Henderson Global Life Sciences S’s management team is just average, but a solid investment process still helps this strategy retain its Morningstar Quantitative Rating of Bronze. Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-costliest quintile among peers.
- NAV / 1-Day Return 64.05 / 0.47 %
- Total Assets 4.7 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.180%
- Distribution Fee Level Above Average
- Share Class Type No Load
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.00
- Turnover 21%
Morningstar’s Analysis JFNSX
Will JFNSX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.